Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Unity Software Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.26 (market cap $8.04B), while Unity Software Inc trades at $31.04 (market cap $13.86B). The key difference: Unity Software Inc is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Unity Software Inc nearer its low. Which is the better fit depends on your goals.
| BIO | U | |
|---|---|---|
Market Cap | $8.04B | $13.86B |
Sector | Health | Technology |
52-Week High | $339.75 | $49.47 |
52-Week Low | $241.71 | $17.13 |
Enterprise Value | $7.85B | $13.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Unity Software (U) trades at $30.68, down 0.68% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $36.50. Recent earnings show mixed results, with Q3 2025 beating expectations but subsequent quarters missing, while revenue remains stable around $1.8 billion. The company maintains strong gross margins of 62.79% but reports negative net income margins, reflecting ongoing profitability challenges amid strategic shifts toward AI and advertising.
The outlook for Unity hinges on its AI integration and cost management, offering upside if execution improves, but risks include persistent losses, high debt, and competitive pressures. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
